Granted Patent
B2
US 12,319,720 · App. 17/823,937 · Granted Jun 3, 2025
Neoantigen vaccines for triple negative breast cancer
Inventors:
William Gillanders (St. Louis, MO); Ted Hansen (North Potomac, MD); S. Peter Goedegebuure (St. Louis, MO)
Assignee:
Washington University
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure is directed to compositions and methods of treating Triple Negative Breast Cancer (TNBC) in a human subject. A method of treating TNBC in a human subject includes administering a therapeutically effective amount of a neoantigen vaccine composition comprising a fusion protein comprising at least one TNBC-associated neoantigen epitope joined to a mutant ubiquitin protein, or a nucleic acid molecule encoding such a protein.
Claims (4)
1. A fusion protein comprising at least one triple negative breast cancer (TNBC)-associated neoantigen epitope joined to a mutant ubiquitin protein, wherein the at least one TNBC-associated neoantigen epitope is LRRC27, and wherein the mutant ubiquitin protein is selected from SEQ ID NO: 1, SEQ ID NO: 1 comprising substitution of a leucine at position 76, and SEQ ID NO: 1 comprising substitution of an isoleucine at position 76.
2. The fusion protein of claim 1 , further comprising at least one additional TNBC-associated neoantigen epitope.
3. A nucleic acid molecule encoding a fusion protein comprising at least one TNBC-associated neoantigen epitope joined to a mutant ubiquitin protein, wherein the at least one TNBC-associated neoantigen epitope is LRRC27, and wherein the mutant ubiquitin protein is selected from SEQ ID NO: 1, SEQ ID NO: 1 comprising substitution of a leucine at position 76, and SEQ ID NO: 1 comprising substitution of an isoleucine at position 76.
4. A method of treating Triple Negative Breast Cancer (TNBC) in an individual, the method comprising administering a therapeutically effective amount of a fusion protein, comprising at least one TNBC-associated neoantigen epitope joined to a mutant ubiquitin protein, wherein the at least one TNBC-associated neoantigen epitope is LRRC27, and wherein the mutant ubiquitin protein is selected from SEQ ID NO: 1, SEQ ID NO: 1 comprising substitution of a leucine at position 76, and SEQ ID NO: 1 comprising substitution of an isoleucine at position 76.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 17, 2022
From: GILLANDERS, WILLIAM; HANSEN, TED; GOEDEGEBUURE, S. PETER
To: WASHINGTON UNIVERSITY
Reel/Frame 061445/0016 →
Continuity (2)
Provisional Application
63239312
· Aug 31, 2021
References Cited (58)
US 20090221682A1
· Maithal
· 2009
[cited by examiner]
US 20190381160A1
· Petit et al.
· 2019
[cited by applicant]
WO WO2011110953
· 2011
[cited by examiner]
WO 2018102585A1
· 2018
[cited by applicant]
WO 2021046466A1
· 2021
[cited by applicant]
Bhattacharya et al., Plos One 12(3): e0171355. https://doi.org/10.1371/journal.pone.0171355; 22 pages total (Year: 2017).
[cited by examiner]
Fenton et al., Medicinal Chemistry Research (2020) 29:1133-1146 (Year: 2020).
[cited by examiner]
Moody et al., Curr Opin Endocrinol Diabetes Obes 2016, 23:38-47 (Year: 2016).
[cited by examiner]
Lehman et al., PLoS ONE (2016), 11(6): e0157368 doi: 10.1371/journal.pone.0157368 (Year: 2016).
[cited by examiner]
Alexander et al. (2002) A decaepitope polypeptide primes for multiple CD8+ IFN-gamma and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. J Immunol. vol. 168, No. 12, pp. …
[cited by applicant]
Aslakson et al. (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. vol. 52, No. 6, pp. 1399-1405.
[cited by applicant]
Bijker et al. (2007) CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol. vol. 179, No. 8, pp. 50…
[cited by applicant]
Bins et al. (2005) A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med. vol. 11, No. 8, pp. 899-904.
[cited by applicant]
Carreno et al. (2015) Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. vol. 348, No. 6236, pp. 803-808.
[cited by applicant]
Dantuma et al. (2000) Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol. vol. 18, No. 5, pp. 538-543.
[cited by applicant]
Davis et al. (1993) DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet. vol. 2, No. 11, pp. 1847-1851.
[cited by applicant]
Duperret et al. (2019) A synthetic DNA, multi-neoantigen vaccine drives predominately MHC class I CD8(+) T-cell responses, impacting tumor challenge. Cancer Immunol Res. vol. 7, No. 2, pp. 174-182.
[cited by applicant]
Ewens et al. (2005) Distant metastasis from subcutaneously grown E0771 medullary breast adenocarcinoma. Anticancer Res. vol. 25, No. 6B, pp. 3905-3915.
[cited by applicant]
Ferraro et al. (2011) Clinical applications of DNA vaccines: current progress. Clin Infect Dis. vol. 53, No. 3, pp. 296-302.
[cited by applicant]
Fynan et al. (1993) DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A. vol. 90, No. 24, pp. 11478-11482.
[cited by applicant]
Gubin et al. (2014) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. vol. 515, No. 7528, pp. 577-581.
[cited by applicant]
Hilf et al. (2019) Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. vol. 565, No. 7738, pp. 240-245.
[cited by applicant]
Hundal et al. (2016) pVAC-Seq: a genome-guided in silico approach to identifying tumor neoantigens. Genome Med. vol. 8, No. 11, 11 pages.
[cited by applicant]
Hundal et al. (2020) pVACtools: a computational toolkit to identify and visualize cancer neoantigens. Cancer Immunol Res. vol. 8, No. 3, pp. 409-420.
[cited by applicant]
Johnson et al. (1992) Ubiquitin as a degradation signal. EMBO J. vol. 11, No. 2, pp. 497-505.
[cited by applicant]
Johnson et al. (1995) A proteolytic pathway that recognizes ubiquitin as a degradation signal. J Biol Chem. vol. 270, No. 29, pp. 17442-17456.
[cited by applicant]
Jurtz et al. (2017) NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol. vol. 199, No. 9, pp. 3360-3368.
[cited by applicant]
Keskin et al. (2019) Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. vol. 565, No. 7738, pp. 234-239.
[cited by applicant]
Kim et al. (2008) Ubiquitin signals autophagic degradation of cytosolic proteins and peroxisomes. Proc Natl Acad Sci U S A. vol. 105, No. 52, pp. 20567-20574.
[cited by applicant]
Kim et al. (2010) Single-chain HLA-A2 Mhc trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection. J Immunol. vol. 184, No. 8, pp. 4423-4430.
[cited by applicant]
Kreiter et al. (2012) Targeting the tumor mutanome for personalized vaccination therapy. Oncoimmunology. vol. 1, No. 5, pp. 768-769.
[cited by applicant]
Kutzler et al. (2008) DNA vaccines: ready for prime time? Nat Rev Genet. vol. 9, No. 10, pp. 776-788.
[cited by applicant]
Lelekakis et al. (1999) A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. vol. 17, No. 2, pp. 163-170.
[cited by applicant]
Levy et al. (2007) A melanoma multiepitope polypeptide induces specific CD8+ T-cell response. Cell Immunol. vol. 250, No. 1-2, pp. 24-30.
[cited by applicant]
Li et al. (2010) Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens. Vaccine. vol. 28, No. 8, pp. 1911-1918.
[cited by applicant]
Li et al. (2011) Cancer genome sequencing and its implications for personalized cancer vaccines. Cancers (Basel). vol. 3, No. 4, pp. 4191-4211.
[cited by applicant]
Li et al. (2017) Preclinical and clinical development of neoantigen vaccines. Ann Oncol. vol. 28, suppl_12, pp. xii11- xii17.
[cited by applicant]
Li et al. (Apr. 2021) Optimized polyepitope neoantigen DNA vaccines elicit neoantigen—specific immune responses in preclinical models and in clinical translation. Genome Medicine. vol. 13, 56, 13 pages.
[cited by applicant]
Lybarger et al. (2003) Virus subversion of the MHC class I peptide-loading complex. Immunity. vol. 18, No. 1, pp. 121-130.
[cited by applicant]
Matsushita et al. (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. vol. 482, No. 7385, pp. 400-404.
[cited by applicant]
Neisig et al. (1995) Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. J Immunol. vol. 154, No.…
[cited by applicant]
Ott et al. (2017) An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. vol. 547, No. 7662, pp. 217-221.
[cited by applicant]
Pascolo et al. (1997) HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med. vol. 185, …
[cited by applicant]
Ribas et al. (2018) Cancer immunotherapy using checkpoint blockade. Science. vol. 359, No. 6382, pp. 1350-1355.
[cited by applicant]
Rizvi et al. (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. vol. 348, No. 6230, pp. 124-128.
[cited by applicant]
Rock et al. (1999) Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol. vol. 17, No. 1, pp. 739-779.
[cited by applicant]
Sahin et al. (2017) Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. vol. 547, No. 7662, pp. 222-226.
[cited by applicant]
Snell et al. (1948) Tumor immunity in mice, induced with lyophilized tissue, as influenced by tumor strain, host strain, source of tissue, and dosage. Cancer Res. vol. 8, No. 9, pp. 429-437.
[cited by applicant]
Tang et al. (1992) Genetic immunization is a simple method for eliciting an immune response. Nature. vol. 356, No. 6365, pp. 152-154.
[cited by applicant]
Topalian et al. (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. vol. 27, No. 4, pp. 450-461.
[cited by applicant]
Ulmer et al. (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. vol. 259, No. 5102, pp. 1745-1749.
[cited by applicant]
Varshavsky (1997) The N-end rule pathway of protein degradation. Genes Cells. vol. 2, No. 1, pp. 13-28.
[cited by applicant]
Velders et al. (2001) Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol. vol. 166, No. 9, pp. 5366-5373.
[cited by applicant]
Wang et al. (2013) Decoupling the role of ubiquitination for the dislocation versus degradation of major histocompatibility complex (MHC) class I proteins during endoplasmic reticulum-associated degradation(ERAD). J Bio…
[cited by applicant]
Washington University in St. Louis (2020) BioProject PRJNA685845. Sequence Read Archive (SRA). https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA685845. Accessed Jul. 13, 2023. 1 page.
[cited by applicant]
Wei et al. (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. vol. 8, No. 9, pp. 1069-1086.
[cited by applicant]
Zhang et al. (2017) Breast cancer neoantigens can induce CD8+ T-cell responses and antitumor immunity. Cancer Immunol Res. vol. 5, No. 7, pp. 516-523.
[cited by applicant]